Basel Medical Group Ltd Offers 6 Million Units at US$1.33 Per Unit

Singapore, Oct. 08, 2026 /CourierPR/ -- Basel Medical Group Ltd, a Singapore-based provider of orthopedic and trauma services, has entered into an agreement to issue and sell 6,000,000 units (the “Units”) at a public offering price of US$1.33 per Unit. Each Unit consists of one ordinary share with no par value (each an “Ordinary Share”) and one warrant (“Common Warrant”), each to purchase one Ordinary Share.

The total gross proceeds to the Company from the offering, before deducting commissions and offering expenses, will be US$7.98 million. The Company estimates that its net proceeds from this offering will be approximately US$7.28 million. The Ordinary Shares issued and to be issued upon warrant exercise and pursuant to this offering are registered pursuant to the Company’s effective registration statement on Form F-1 (File No. 333-298988) (the “Registration Statement”) and will be freely tradeable without restriction following the closing of this offering.

Each Common Warrant is exercisable immediately on the date of issuance at an exercise price per share equal to 110% of the public offering price of each Unit sold in this offering and will expire five years from the date of issuance. A holder of Common Warrants may, at any time following the closing of this offering within the exercise period and in its sole discretion, exercise its Common Warrants in whole or in part by means of a zero cash exercise price option, in which the holder will receive the number of Ordinary Shares that would be issuable upon a cash exercise of the Common Warrant, without payment of additional consideration, or a total of 6,000,000 additional Ordinary Shares in the aggregate. As a result, the Company will likely not receive any additional funds and does not expect to receive any additional funds upon the exercise of the Common Warrants. If all of the 6,000,000 Common Warrants offered to investors in this offering are exercised on a zero cash basis, an aggregate of 6,000,000 Ordinary Shares would be issued upon such zero cash exercise without payment to the Company of any additional cash.

Immediately prior to this offering, the Company had a total of 1,582,111 Ordinary Shares issued and outstanding. Immediately upon the completion of the offering, the Company will have a total of 7,582,111 Ordinary Shares issued and outstanding and a total of 6,000,000 Common Warrants issued and outstanding.

The Company and all of its executive officers, directors, and certain shareholders beneficially owning 5.0% or more of its ordinary shares prior to this offering have entered into lock-up agreements in connection with the offering. Under these agreements, the Company and each of these persons may not, without the prior written approval of the Placement Agent, offer, sell, contract to sell, or otherwise dispose of or hedge Ordinary Shares or securities convertible into or exchangeable for Ordinary Shares, subject to certain exceptions. The restrictions contained in these agreements will be in effect for a period of 180 days for the Company and 180 days for the executive officers, directors, and such shareholders, after the date of the closing of this offering.

Cathay Securities, Inc. is acting as exclusive placement agent in connection with this offering. Sichenzia Ross Ference Carmel LLP is acting as counsel to the Company regarding U.S. securities law matters. Hunter Taubman Fischer & Li LLC is acting as U.S. securities counsel for the placement agent.

The securities described above are being offered pursuant to the Registration Statement, which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on September 29, 2026. The offering is being made only by means of a prospectus which is a part of the Registration Statement. A preliminary prospectus relating to the offering has been filed with the SEC.

Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more complete information about the Company and the offering. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company’s securities in any state or jurisdiction in which such offers, solicitations or sales would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. Any offers, solicitations, or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

Basel Medical Group Ltd serves as the holding company of the group and conducts its operations through its operating subsidiaries based in Singapore. The company's services include orthopedic and trauma services, sports medicine, orthopedic procedures and surgery, neurosurgical treatments, executive health screening services, occupational medicine, rehabilitation, mental and women’s health, and general medical practices. Over the last 20 years, the group has forged strong and lasting relationships with a wide corporation clientele, particularly those in the construction, marine, and oil & gas industries.